Reposted by Justo P. Castaño 🔬🧬🧫 #SinCienciaNoHayFuturo
www.diariocordoba.com/opinion/2026...
diariocordoba.com
Las guerras de nuestros bisabuelos… ¿las de nuestros hijos?
Creo que debería haber espacio para ejercer una reflexión serena sobre lo ocurrido en este mes de agosto en Ceuta, aunque es tremendamente difícil abstraerse de toda la tensión acumulada en las redes,...
![[Endocrine Oncology logo]
Comprehensive somatic profiling of gastroenteropancreatic neuroendocrine neoplasms. By Chirayu Mohindroo et al.
Figure 2. Mutational heatmap of pathogenic and likely pathogenic variants across tumors from 111 patients. Each row represents a tumor sample, and each column represents a gene. The colored tiles indicate the presence of pathogenic or likely pathogenic mutations. Gray tiles indicate unavailable data for the corresponding variable and sample, except where otherwise specified in the color legend. The heatmap illustrates the distribution and frequency of clinically relevant mutations across the cohort, alongside key clinical characteristics. Genes were grouped into broad functional categories according to their predominant biological roles described in the literature; these categories are descriptive and not mutually exclusive, as individual genes may participate in multiple biological pathways.
Endocr Oncol (2026) 6 (1): e260044. doi.org/10.1530/EO-26-0044.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiao3xvnkohfne7oi6jzpx6rr4ghh6yi4hirp5drcyiudghuqa2dp4)
![Corticotroph tumour progression 37 years after bilateral adrenalectomy with temozolomide-naive response to pembrolizumab
By Edward Mignone et al.
Figure 1. Top left: T1-weighted gadolinium-enhanced coronal magnetic resonance imaging (MRI) of the patient’s sella. Residual tumour in the right cavernous sinus (6 × 4 mm), 3 months after transsphenoidal resection, before pembrolizumab. Top right: reduction in size of tumour remnant in the right cavernous sinus (4 × 4 mm) after 15 months of pembrolizumab and 12 months after radiosurgery. Bottom: adrenocorticotropic hormone (ACTH) trend in relation to interventions. ACTH initially declined but then rose after transsphenoidal resection, followed by a significant decline at 2 weeks after radiotherapy completion and 3 months after the initiation of pembrolizumab...Endocr Oncol (2026) 6 (1): e260064. doi.org/10.1530/EO-26-0064.
[Endocrine Oncology logo]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiho7wtkxurr2ffohrhhi6spacehy63rgr36z567poubs25sr6uqku)
![Cytological biomarkers and risk of malignancy in indeterminate thyroid nodules: a systematic review and meta-analysis. By Trille Moberg Fagerhaug et al.
[Endocrine Oncology logo]
Figure 3. Descriptive forest plot showing DOR of markers differentiating benign from malignant nodules with indeterminate FNAC samples. (A) Galectin-3, (B) HBME-1, (C) BRAF, and (D) Galectin-3/HBME-1 co-expression.
Endocr Oncol (2026) 6 (1): e250097. doi.org/10.1530/EO-25-0097.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiehnsye6tvordd3jix7naaotlfqq5ar22mnr5trhql7lq2bechm6u)
![[Endocrine Oncology logo] Current Evidence Across the Treatment Spectrum of Adrenocortical Carcinoma: A Comprehensive Scoping Review. By Angélica María González-Clavijo et al. Figure 1. Evidence map of treatment strategies in adrenocortical carcinoma (ACC). This figure summarizes the distribution, quantity, and direction of available evidence across the five clinical domains examined in this scoping review: surgery, adjuvant therapy, metastatic disease, recurrence, and hormone excess. Each bubble represents a specific intervention or evidence focus within a clinical domain. Bubble size reflects the number of contributing studies, fill color indicates the overall direction of evidence, and shape identifies whether randomized evidence was available. The x-axis groups interventions according to clinical domain, whereas the y-axis displays the principal intervention or evidence category evaluated...Endocr Oncol EO-26-0079. doi.org/10.1530/EO-26-0079](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreigabeetro7bbc3oywjcgkdkonewnzlegxn6r5dsblk7vndrakiaru)
![[Endocrine Oncology logo]
AGK::BRAF fusion activates MAPK signaling, promotes genomic instability, and reduces NIS expression in thyroid cancer cells. By Luiza Sisdelli et al.
Figure 1. Activation of MAPK and PI3K/AKT signaling pathways in PCCL3 thyroid cells expressing pediatric PTC oncogenes. PCCL3 rat thyroid follicular cells were transfected with pBudCE4.1 expression vectors encoding BRAF wild-type (WT), AGK::BRAF, ETV6::NTRK3, RET/PTC1, RET/PTC3, or BRAF V600E, and culture under growth factor-deprived conditions. (A) Representative Western blot analysis showing phosphorylation levels of key components of the MAPK (p-MEK1/2, p-ERK1/2) and PI3K/AKT (p-AKT) pathways, as well as STAT3 activation (p-STAT3 Ser727). Total protein levels are shown as loading control (B) Quantification of phosphorylated proteins normalized to total protein levels across three independent biological replicates. Data are presented as mean ± s.d...Endocr Oncol EO-25-0096. doi.org/10.1530/EO-25-0096.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiecranpa4f7vowkxdjevkd6wsaps3hdya35etuehp4skz6oawzbuu)
![[Endocrine Oncology logo] Beyond mitotane: next-generation therapeutic landscapes in adrenocortical carcinoma. By Keya Kotecha, Katia Mariniello, Leonardo Guasti. Figure 1. Mechanistic landscape for next-generation therapeutic modalities in ACC. (A) Precision targeting via antibody-drug conjugates (ADCs) bypasses traditional immune exclusion by delivering cytotoxic payloads directly to ACC antigens, such as DLK1. After binding to the antigen on the cell surface, ADCs are internalised via endocytosis and trafficked to the endo-lysosomal compartment. Here, the acidic environment and lysosomal proteases facilitate the proteolytic cleavage or hydrolytic uncoupling of the payload from the antibody, allowing the active drug to be released into the cytosol. When the payload (such as the PBD dimer used in ADCT-701) is hydrophobic (lipophilic) and neutrally charged, it possesses the unique ability to diffuse across the plasma membrane of...Endocr Oncol EO-26-0040. doi.org/10.1530/EO-26-0040.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreibwa6wu25zjodywcp5pmappr7emfsz662yhf2kfdw3iwui226r2ma)
